Acamprosate_Calcium: profile and news

Replidyne and Forest Laboratories Announce FDA Acceptance for ...  Feb 23, 2006
...receptor blocker and diuretic combination product indicated for the second- line treatment of hypertension; Campral (R) * (acamprosate calcium), a glutamate ... - Finanzen.net,

Replidyne and Forest Laboratories Announce Faropenem Medoxomil ...  Feb 13, 2006
...receptor blocker and diuretic combination product indicated for the second- line treatment of hypertension; Campral(R)* (acamprosate calcium), a glutamate ... - PR Newswire (press release),

The CDC estimates 46.2 million Adults in the US Smoke Cigarettes ...  Jan 26, 2006
The 2004 approval and 2005 market introduction of acamprosate calcium (Forest Laboratories Campral) for treatment of alcohol dependence and the 2002 ... - Business Wire (press release),

Forest Laboratories, Inc. Reports Q3'06 Diluted Earnings Per Share ...  Jan 17, 2006
...receptor blocker and diuretic combination product indicated for the second-line treatment of hypertension; Campral(R) * (acamprosate calcium), a glutamate ... - MSN Money

Mylan Laboratories and Forest Laboratories Announce Nebivolol ...  Jan 12, 2006
...receptor blocker and diuretic combination product indicated for the second- line treatment of hypertension; Campral(R) * (acamprosate calcium), a glutamate ... - PharmaLive.com (press release),

Gedeon Richter and Forest Laboratories Expand Relationship with ...  Nov 28, 2005
...receptor blocker and diuretic combination product indicated for the second-line treatment of hypertension; Campral®* (acamprosate calcium), a glutamate ... - Yahoo! News (press release)

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce ...  Sep 28, 2005
...receptor blocker and diuretic combination product indicated for the second-line treatment of hypertension; Campral®*(acamprosate calcium), a glutamate ... - Yahoo! News (press release)

Somaxon Pharmaceuticals, Inc. Initiates Second Phase III Clinical ...  Sep 20, 2005
...cessation. The company is also developing a new formulation of acamprosate calcium for the treatment of movement disorders. Somaxon ... - Genetic Engineering News,

Oral Solution Formulation of Namenda(R), the Only FDA-Approved ...  Aug 18, 2005
...receptor blocker and diuretic combination product indicated for the second-line treatment of hypertension; Campral(R)*(acamprosate calcium), a glutamate ... - PR Newswire (press release),